GDUFA Self-Identification Woes Can’t Deflate Industry, FDA Enthusiasm
Executive Summary
As the grace period nears its close, industry officials say they expected problems getting generic drug manufacturing facilities to self-identify under the new user fee requirement; meanwhile, FDA expects to hire nearly three times the staff in the Office of Generic Drugs to meet GDUFA commitments.
You may also be interested in...
FDA Doubles Estimated Time Needed For DMF Completeness Assessment
FDA now says Type II active ingredient drug master files should be submitted six months before the referencing ANDA to allow enough time for the completeness assessment. Delays could mean refuse-to-receive action for the ANDA.
FDA Doubles Estimated Time Needed For DMF Completeness Assessment
FDA now says Type II active ingredient drug master files should be submitted six months before the referencing ANDA to allow enough time for the completeness assessment. Delays could mean refuse-to-receive action for the ANDA.
GDUFA: Fee Avoidance Affects Rates Again
Industry avoided application supplement fees by using CBE submissions instead, forcing FDA to change its estimates and sending generic drug user fees higher.